Page Title

Erstes Zentrum in Südafrika für pan-afrikanischen Phase-III-Studie gegen Tuberkulose initiiert

Vakzine Projekt Management GmbH (VPM) announces that the first clinical center in South Africa has been initiated in a large phase III trial (priMe) to assess the efficacy and safety of the novel TB vaccine – VPM1002 – in comparison with BCG in healthy newborn infants. The clinical centers in Tanzania, Uganda and Gabon will follow in the next weeks.